Of two potential suitors for biotech Genzyme Corp., industry insiders say Sanofi-Aventis is a far more likely buyer than GlaxoSmithKline PLC, which already has a presence in rare diseases.
*For more on this story, read the full Reuters article.
Of two potential suitors for biotech Genzyme Corp., industry insiders say Sanofi-Aventis is a far more likely buyer than GlaxoSmithKline PLC, which already has a presence in rare diseases.
*For more on this story, read the full Reuters article.
Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!